Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation
Huw D. Lewis(GlaxoSmithKline (United Kingdom)), John Liddle(GlaxoSmithKline (United Kingdom)), Jim Coote(GlaxoSmithKline (United Kingdom)), Stephen J. Atkinson(GlaxoSmithKline (United Kingdom)), Michael D. Barker(GlaxoSmithKline (United Kingdom)), B.D. Bax(GlaxoSmithKline (United Kingdom)), Kevin L. Bicker(Scripps Research Institute), Ryan P. Bingham(GlaxoSmithKline (United Kingdom)), Matthew Campbell(GlaxoSmithKline (United Kingdom)), Yu Hua Chen(GlaxoSmithKline (United Kingdom)), Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Peter D. Craggs(GlaxoSmithKline (United Kingdom)), Rob P. Davis(GlaxoSmithKline (United Kingdom)), Dirk Eberhard, Gérard Joberty, Kenneth Lind(GlaxoSmithKline (United States)), Kelly Locke(GlaxoSmithKline (United Kingdom)), Claire Maller(GlaxoSmithKline (United Kingdom)), Kimberly Martinod(Boston Children's Hospital), Chris Patten(GlaxoSmithKline (United Kingdom)), Oxana Polyakova(GlaxoSmithKline (United Kingdom)), Cecil Rise(GlaxoSmithKline (United States)), Martin Rüdiger(GlaxoSmithKline (United Kingdom)), Robert J. Sheppard(GlaxoSmithKline (United Kingdom)), Daniel J. Slade(Scripps Research Institute), Pamela J. Thomas(GlaxoSmithKline (United Kingdom)), Jim Thorpe(GlaxoSmithKline (United Kingdom)), Gang Yao(GlaxoSmithKline (United States)), Gerard Drewes, Denisa D. Wagner(Boston Children's Hospital), Paul R Thompson(Scripps Research Institute), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), David M. Wilson(GlaxoSmithKline (United Kingdom))
Cited by 754Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis